Eloxx Pharmaceuticals, Inc (ELOX)

Etorro trading 970x250
Eloxx Pharmaceuticals, Inc (ELOX) Logo

About Eloxx Pharmaceuticals, Inc

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts. Address: 950 Winter Street, Waltham, MA, United States, 02451

Eloxx Pharmaceuticals, Inc News and around…

Latest news about Eloxx Pharmaceuticals, Inc (ELOX) common stock and company :

71 Biggest Movers From Yesterday
20 May, 2022 FinancialContent

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA ...

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
10 May, 2022 Yahoo! Finance

Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected at the end of the first half of 2022 Expanded development of ELX-02 for the treatment of Alport syndrome, a rare kidney genetic disorder, with Phase 2 expected to start in second half of 2022 Expect to submit an Investigational New Drug (IND) application for the inhaled

12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Apr, 2022 FinancialContent

Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares moved upwards by 9.9% to $1.0 during Wednesday's after-market session. The ...

Eloxx to Test Its Lead Product Candidate, ELX-02, In Rare Kidney Disease
31 Mar, 2022 FinancialContent

Eloxx Pharmaceuticals Inc(NASDAQ: ELOX)expanded the ELX-02 development programto include the treatment of Alport ...

Recap: Eloxx Pharmaceuticals Q4 Earnings
31 Mar, 2022 FinancialContent

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's ...

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update
31 Mar, 2022 Yahoo! Finance

Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program New development program for ELX-02 for the treatment of Alport syndrome, a rare kidney genetic disorder; initiation of proof-of-concept clinical trial expected in second half of 2022 On track to start First in Human Phas

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome
30 Mar, 2022 Yahoo! Finance

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney Initiation of proof-of-concept clinical trial expected in second half of 2022; topline results expected in first half of 2023 WATERTOWN, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, toda

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
29 Mar, 2022 Yahoo! Finance

Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from cystic fibrosis Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 WATERTOWN, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received additional

12 Health Care Stocks Moving In Monday's After-Market Session
27 Dec, 2021 FinancialContent

Gainers OptiNose (NASDAQ:OPTN) shares moved upwards by 9.81% to $1.79 during Monday's after-market session. Trading volume for this ...

65 Biggest Movers From Yesterday
21 Dec, 2021 FinancialContent

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported ...

38 Stocks Moving In Monday's Mid-Day Session
20 Dec, 2021 FinancialContent

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
20 Dec, 2021 FinancialContent

Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
20 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

25 Stocks Moving in Monday's Pre-Market Session
20 Dec, 2021 FinancialContent

Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to ...

12 Health Care Stocks Moving In Friday's After-Market Session
17 Dec, 2021 FinancialContent

Gainers GBS (NASDAQ:GBS) stock rose 14.28% to $1.44 during Friday's after-market session. At the close, GBS's ...

12 Health Care Stocks Moving In Friday's Intraday Session
17 Dec, 2021 FinancialContent

Gainers Genfit (NASDAQ:GNFT) stock moved upwards by 43.97% to $4.78 during Friday's regular session. Genfit's ...

Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
17 Dec, 2021 FinancialContent

Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ:DH) was changed from ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
17 Dec, 2021 FinancialContent

Gainers Genfit (NASDAQ:GNFT) stock moved upwards by 38.55% to $4.6 during Friday's pre-market session. The market ...

12 Health Care Stocks Moving In Thursday's After-Market Session
16 Dec, 2021 FinancialContent

Gainers Eloxx Pharmaceuticals (NASDAQ:ELOX) shares increased by 12.25% to $0.74 during Thursday's after-market ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
30 Nov, 2021 FinancialContent

Gainers Lannett (NYSE:LCI) shares rose 11.61% to $1.73 during Tuesday's after-market session. The market value of their outstanding ...

Read Why Eloxx Pharma Stock Continues To Fall
18 Nov, 2021 FinancialContent

H.C. Wainwrightlowered the price targetonEloxx Pharmaceuticals Inc(NASDAQ: ELOX) to $1 from $2 and reiterated ...

12 Health Care Stocks Moving In Thursday's Intraday Session
18 Nov, 2021 FinancialContent

Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Nov, 2021 FinancialContent

Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) stock increased by 78.28% to $37.94 during Thursday's pre-market ...

10 Biggest Price Target Changes For Thursday
18 Nov, 2021 FinancialContent

Telsey Advisory Group lifted Lowe's Companies, Inc. (NYSE: LOW) price target from $250 to $275. Lowe's shares rose 0.1% to ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Nov, 2021 FinancialContent

Gainers EyePoint Pharmaceuticals (NASDAQ:EYPT) shares moved upwards by 25.83% to $17.68 during Wednesday's regular session. The ...

Eloxx Shares Slump As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors
17 Nov, 2021 FinancialContent

Eloxx Pharmaceuticals Inc(NASDAQ: ELOX)posted topline resultsfrom the monotherapy arms of its Phase 2 trial of ...

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
17 Nov, 2021 Yahoo! Finance

ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, N

Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update
09 Nov, 2021 Yahoo! Finance

Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received FDA Fast Track Designation for ELX-02 for the Treatment of CF Patients with Nonsense Mutations Hosted Call and Webcast on CF Programs Featuring CF Expert Dr. Eitan Kerem Appointed Ali Hariri, M.D. as Chief Medical Officer Entered into Senior Debt Facility from Hercules Capital for Borrowings of Up to $30 Million WATERTOWN, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) --

11 Best Penny Stocks To Buy According To Hedge Funds
15 Oct, 2021 Yahoo! Finance

In this article, we discuss the 11 best penny stocks to buy according to hedge funds. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Penny Stocks To Buy According To Hedge Funds. Hedge funds do not normally invest in penny stocks, primarily because of the risk […]

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Weighed On By Its Debt Load?
10 Oct, 2021 Yahoo! Finance

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Eloxx Pharmaceuticals, Inc (ELOX) is a NASDAQ Common Stock listed in , ,

970x250